Acetrizoate Sodium

CHEMBL1201045 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
578.8 g/mol
LogP
Phase
4

A water-soluble iodine-based contrast agent that was historically used in X-ray imaging procedures to visualize body cavities, blood vessels, and the urinary tract by absorbing X-rays and creating visible contrast. It has been replaced in most applications by safer, lower-osmolality contrast media that cause fewer adverse reactions. Its use in modern radiology is largely historical.

Moleküler Ağırlık

578,8400 g/mol

TPSA

69,20 Ų

Etki Mekanizması

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)Nc1c(I)cc(I)c(C(=O)[O-])c1I.O.[Na+]

InChI

InChI=1S/C9H6I3NO3.Na.H2O/c1-3(14)13-8-5(11)2-4(10)6(7(8)12)9(15)16;;/h2H,1H3,(H,13,14)(H,15,16);;1H2/q;+1;/p-1

Molecular Formula

C9H5I3NNaO3

HBD / HBA

1 / 3

Döndürülebilir Bağlar

2

Ağır Atomlar

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A water-soluble iodine-based contrast agent that was historically used in X-ray imaging procedures to visualize body cavities, blood vessels, and the urinary tract by absorbing X-rays and creating visible contrast. It has been replaced in most applications by safer, lower-osmolality contrast media that cause fewer adverse reactions. Its use in modern radiology is largely historical.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Acetrizoate Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201045. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23665874. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.